NTX is an abbreviation for urinary collagen type 1 cross-linked N-telopeptide
As expected, urinary collagen type I cross-linked N-telopeptide
, a biomarker of bone resorption, increased with placebo, compared with a significant 47% decrease with odanacatib.
At the same time, urinary N-telopeptide
level, a marker of bone resorption, decreased by 20% at 3 months, 33% at 12 months, and 54% at 24 months.
Additionally, compared with placebo, treatment with nitroglycerin was significantly associated with an increase in bone-specific alkaline phosphatase, a marker of bone formation; and a decrease in urine N-telopeptide
, a marker of bone resorption.
The effect on gonadotropins translated in a dose related fashion to maintenance of low estradiol levels over the six week period without inducing severe hot flashes or excessive bone resorption as determined by n-telopeptide
Bone alkaline phosphatase activity and serum N-telopeptide
concentration increased appreciably over the same period of time.
Markers of bone turnover include bone-specific alkaline phosphatase, osteocalcin, and the collagen cross-links, deoxypyridinoline, C-telopeptide (CTX), and N-telopeptide
Early changes in serum N-telopeptide
and C-telopeptide cross-linked collagen type I predict long-term response to alendronate therapy in elderly women.
Interestingly, urinary N-telopeptide
excretion was higher with high zinc than with
The study evaluated patients whose urinary N-telopeptide
(uNTx) levels had not normalized despite treatment with IV bisphosphonates.
Mean change from baseline for elagolix 150 mg qd remained at close to 0% at Week 48, with n-telopeptide
values remained close to a mean of 10 nM BCE (normal range 6-19 nM BCE for this age group).
The study's primary end points were the 6-month measurements of urine N-telopeptide
of type I collagen corrected by creatinine (NTx) and bone-specific alkaline phosphatase (BSAP).